You searched for: farmacéuticasuspension (Spanska - Engelska)

forma farmacéuticasuspension inyectable suspension inyectable
suspension for injection suspension for injection

15 microgramos ha**15 microgramos ha**15 microgramos ha** por dosis de 0,5 ml.............................................................................................. * propagado en células madin-darby canine kidney (mdck) ** hemaglutininala vacuna cumple con la recomendación de la oms (hemisferio norte) y con la decisión de la ue para la estación 2007/2008.para consultar la lista completa de excipientes, ver sección 6.1.3.forma farmacÉuticasuspensión inyectable en jeringa precargada.transparente a ligeramente opalescente.
* propagated in madin darby canine kidney (mdck) cells ** haemagglutinin the vaccine complies with the who recommendation (northern hemisphere) and eu 2007/2008 season.for a full list of excipients, see section 6.1.3.pharmaceutical form suspension for injection in pre-filled syringe clear to slightly opalescent.4.clinical particulars 4.1 therapeutic indications prophylaxis of influenza for adults, especially in those who run an increased complications.the use of optaflu should be based on official recommendations.4.2 posology and method of administration adults:0.5 ml.immunisation should be carried out by intramuscular (into the deltoid muscle) children and adolescents ( 18 years of age):2/24 optaflu is not recommended for use in children and adolescents below 18 years on safety and efficacy (see section 5.1) .4.3 contraindications hypersensitivity to the active substances or to any of the excipients.15 micrograms ha**15 micrograms ha**15 micrograms ha** per 0.5 ml dose